A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

03 Dec 2024 Trial has been amended and expanded to further evaluate efficacy at the target dose and target third line patient population.
03 Dec 2024 According to a MAIA Biotechnology media release, company expects to start enrolling new patients in the expansion of THIO-101 in the near future.
03 Dec 2024 According to a MAIA Biotechnology media release, company announced that it has amended the 2021 clinical supply agreement with Regeneron for the expansion portion of THIO-101.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com